Navigation Links
Frost & Sullivan: Clinical and Cost Benefits to Promote Uptake of Advanced Wound Management Technologies Across Europe
Date:5/18/2009

LONDON, May 18 /PRNewswire/ -- The advanced wound management market in Europe is experiencing high growth due to the heightened need for better and more cost-effective treatment. As a result, the market is expanding strongly despite significant hurdles, including intense competition and low reimbursement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.medicaldevices.frost.com), Western European Advanced Wound Management Market, finds that the market earned revenues of $1.52 billion in 2008 and estimates this to reach $4.35 billion in 2015. The following segments are covered in the research: moist wound dressings segment, antimicrobial wound dressings segment, NPWT segment and advanced therapies segment.

"Rising awareness about chronic wound care in hospitals and home care is supporting the expansion of the advanced wound care market in Europe," notes Frost & Sullivan Research Associate Sreevidhya Praveen. "The market is gaining in popularity against a backdrop of efforts to reduce healthcare expenditure."

Advanced wound care products enable speedy recovery from wounds. Therefore, they help curtail healthcare expenditure. Due to the clinical and cost benefits that they offer, demand for such advanced wound management products is increasing. The rising incidence of chronic wounds due to an expanding diabetic population, together with an ageing population across Western Europe is also fuelling the uptake of advanced wound care devices.

Changing healthcare systems across Europe are promoting the growth of the advanced wound care products market; physicians are mostly advised to presc
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Frost & Sullivan Cites Gearworks for Creativity and Customer Service in the Home Healthcare Market
2. Focus on Rapid Medical Response to Improve the Quality of Healthcare and Drive the Ambulance Services Market in Europe, According to Frost & Sullivan
3. Frost & Sullivan Acknowledges Sypris for High-Quality Calibration Solutions
4. Affordable and Flexible CRM Solutions - Key to Drive Investments from Pharmaceutical Companies, Notes Frost & Sullivan
5. Not All Gloomy for African Healthcare Markets: Frost & Sullivan Finds Potential Despite the Recession
6. Frost & Sullivan Award Reinforces Outstanding Product Line Strategy by SIRS-Lab
7. Frost & Sullivan: Shift from Analog Mammography Systems to Digital Mammography Systems Will Boost the European Mammography Systems Market
8. South Africa not Gaining the Full Benefit of PPPs in the Healthcare Sector, Says Frost & Sullivan
9. Personalized Medicine Makes Significant Headway Following the Rapid Evolution of U.S. Molecular Diagnostics Market, Finds Frost & Sullivan
10. Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe
11. Higher Outlays and Improved Regulatory Enforcement Create Opportunities in the Kenyan Healthcare Industry, Reveals Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 1VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 2VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 1VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 1Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 3